Volume 3.28 | Jul 27

Prostate Cell News 3.28 July 27, 2012
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter

Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model
Researchers found that dual targeting of the Akt and mTOR signaling pathways with their respective inhibitors, is highly effective for inhibiting castration-resistant prostate cancer in preclinical studies in vivo using a refined genetically-engineered mouse model of the disease. [Cancer Res] Abstract

[Free Webinar] ALDH+ Cancer Precursor Cells in Drug Response Prediction - Watch Now.

PUBLICATIONS (Ranked by impact factor of the journal)


New Therapy Targeting Differential Androgen Receptor Signaling in Prostate Cancer Stem/Progenitor vs Non-Stem/Progenitor cells
Scientists found that targeting prostate cancer (PCa) non-stem/progenitor cells with androgen receptor (AR) degradation enhancer ASC-J9® and targeting PCa stem/progenitor cells with 5-AZA and γ-TT resulted in significant suppression of the PCa at the castration resistant stage. [J Mol Cell Biol] Abstract

Anisamide-Targeted Cyclodextrin Nanoparticles for siRNA Delivery to Prostate Tumors in Mice
Researchers synthesized and compared a hepta-guanidino-β-cyclodextrin, its hepta-PEG conjugate, and the corresponding anisamide-terminated PEG conjugate as delivery vectors for siRNA to prostate cancer cells and tumors in vivo. [Biomaterials] Abstract

c-Myc Expression and MEK1 Induced Erk2 Nuclear Localization are Required for TGF-Beta Induced Epithelial-Mesenchymal Transition and Invasion in Prostate Cancer
Investigators showed that expression of the transcription factor c-myc, which is phosphorlyated by Erk2, is required for epithelial to mesenchymal transitions. [Carcinogenesis] Abstract

Distinct Roles of AKT Isoforms in Regulating β1-Integrin Activity, Migration and Invasion in Prostate Cancer
Validation experiments investigating all three AKT isoforms demonstrated that both AKT1 and AKT2 function as negative regulators of cell migration and invasion in PC3 prostate cancer cells. [Mol Biol Cell] Abstract

Inhibition of Ca2+– Activated Cl Channel ANO1/TMEM16A Expression Suppresses Tumor Growth and Invasiveness in Human Prostate Carcinoma
Scientists provided evidence that upregulation of Ca2+– activated Cl channel ANO1 is involved in the proliferation, progression and pathogenesis of metastatic prostate cancer. [Cancer Lett] Abstract

Silibinin Inhibits Wnt/β-Catenin Signaling by Suppressing Wnt Co-Receptor LRP6 Expression in Human Prostate and Breast Cancer Cells
Researchers found that silibinin was able to suppress endogenous lipoprotein receptor-related protein-6 (LRP6) expression and phosphorylation and block Wnt/β-catenin signaling in prostate cancer PC-3 and DU-145 cells and breast cancer MDA-MB-231 and T-47D cells. [Cell Signal] Abstract

Anti-Proliferative Effect of 23,24-Dihydrocucurbitacin F on Human Prostate Cancer Cells through Induction of Actin Aggregation and Cofilin-Actin Rod Formation
Investigators explored the level and mechanisms of 23,24-dihydrocucurbitacin F toxicity on human prostate cancer cell lines. [Cancer Chemother Pharmacol] Abstract

Fractionated Radiation Alters Oncomir and Tumor Suppressor miRNAs in Human Prostate Cancer Cells
To understand the role of miRNA in regulation of radiation-induced gene expression, investigators analyzed miRNA expression in LNCaP, PC3 and DU145 prostate cancer cells treated with single-dose radiation and fractionated radiation by microarray. [Radiat Res] Abstract

Antitumor Effects of the Novel Quinazolinone MJ-33: Inhibition of Metastasis through the Mitogen-Activated Protein Kinase, AKT, NF-κB and Activator Protein-1 Signaling Pathways in DU145 Human Prostate Cancer Cells
Scientists investigated the anti-metastatic activity of MJ-33 and the signaling pathway of MJ-33 in human prostate cells. [Int J Oncol] Abstract


Prostate Biopsy in Response to a Change in Nadir Prostate Specific Antigen of 0.4 ng/ ml after Treatment with 5α-Reductase Inhibitors Markedly Enhances the Detection Rate of Prostate Cancer
Researchers examined the effect of 5α-reductase inhibitor therapy on prostate cancer detection in men with persistently increased or fluctuating prostate specific antigen and prior negative prostate cancer biopsy. [J Urol] Abstract

A Phase I Study of a Chimeric Monoclonal Antibody Against Interleukin-6, Siltuximab, Combined with Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer

Scientists assessed the safety and tolerability of siltuximab in combination with docetaxel, the pharmacokinetics of docetaxel alone and with siltuximab, and the efficacy and pharmacodynamics of siltuximab plus docetaxel. [Invest New Drugs] Abstract

Do Your Colleagues Know What They Are Missing? Share This Newsletter Now.

New Pan-Canadian Terry Fox Research Institute Network Receives Close to $4 Million to Find Better Tools to Treat Prostate Cancer
A new pan-Canadian network of prostate cancer researchers formed by the Terry Fox Research Institute aims to address whether all men diagnosed with prostate cancer should undergo the same treatment, with approximately $4-million provided by the Terry Fox Foundation and the Canadian Partnership Against Cancer. [The Terry Fox Research Institute] Press Release | Video

Enzalutamide Granted Priority Review by U.S. FDA for the Potential Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated with Chemotherapy
Medivation, Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the new drug application for enzalutamide for the potential treatment of men with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy and granted Priority Review Designation. [Medivation, Inc.] Press Release

New ‘GPS for the Body’ Offers Treatment Option with Minimal Side Effects for Prostate Cancer Patients
Virginia Hospital Center is among the few hospitals along the east coast to offer the new Calypso® System featuring GPS for the Body technology® and Beacon® electromagnetic transponders for patients with certain types of cancer. [PR Newswire] Press Release


Cuts Loom for US Science
A House bill that was passed would give the Obama administration 30 days to work out how to apply a massive cut to federal programs including research. [Obama Administration, United States] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW 2012 International Society for Cell & Gene Therapy of Cancer (ISCGT) Annual Conference
October 4-6, 2012
Singapore, Singapore

Visit our events page to see a complete list of events in the prostate cell community.


Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Postdoctoral Position – Cancer Genomics (University of California)

Postdoctoral Position – Endocrinology of Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Molecular Biology and Genomics (University Hospital Zurich)

Postdoctoral Position – Prostate Cancer Research (University of Texas Southwestern Medical Center)

Postdoctoral Position – Prostate Cancer (BC Cancer Agency)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us